LKL. E. Korotaeva

L. E. Korotaeva

*This is an algorithmically generated author record based on publicly available information.

L. E. Korotaeva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic value of cystatin C for the early diagnosis of diabetic nephropathy

    by V. N. Vasilkova, I. Yu. Pchelin, E. P. Naumenka, Ya. A. Borovets, Yu. I. Yarets, L. E. Korotaeva, I. A. Vasukhina, T. V. Mokhort, Я. А. Боровец, Ю. И. Ярец

    Objective:to assess the clinical significance of cystatin C in the early diagnosis of diabetic nephropathy.Materials and methods.We examined 449 patients with type 1 and type 2 diabetes mellitusolder than 25 years. The laboratory examination of the patients included the measurement of cystatin, creatinine in the blood serum, GFR calculation according to the CKD-EPI equation, and the determination of albuminuria levels.Results.The role of cystatin C as a reliable marker of diabetic nephropathy has been demonstrated: the level of cystatin C ≥ 0.72 mg/L with sensitivity of 90.8 %, specificity of 88.9 %, was associated with a decline of renal function in the diabetic patients (ROC AUC = 0.951).Conclusion.The determination of the level of cystatin C, alone or in conjunction with creatinine, will help to more accurately diagnose GFR and assess the risk of mortality and renal complications in patients with diabetes mellitus.

  • Open Access

    EVALUATION OF THE LEVELS OF FIBROBLAST GROWTH FACTOR (FGF-23) AND INFLAMMATION MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE

    by V.M. Vasilkova, T.V. Mokhort, V.K. Bayrasheva, Л. Е. Коротаева, Yu. I. Yarets, O.N. Shestovets, Ya. A. Borovets, Е. П. Науменко

    Recently, inflammatory and regulatory mechanisms that are involved in the onset and progression of angiopathies in diabetes mellitus (DM), including diabetic kidney disease (DKD), have been studied. In this study, we assessed the levels of fibroblast growth factor-23 (FGF-23) and inflammatory markers in patients with type 2 DM and different stages of chronic kidney disease (CKD). We investigated 64 patients with type 2 DM aged 34-84 years. The results showed significant changes in the levels of FGF-23, tumour necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL-6) with the progression of CKD in patients with type 2 diabetes. Multiple regression analysis demonstrated the presence of an independent interconnection between serum levels of FGF-23 and creatinine.